Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy

Starting soon · Not applicable

Conditions studied: Acute Ischemic Stroke

In brief

Prospective, single-arm, multi-centre study to evaluate the efficacy and safety of the iNstroke 5F thromboaspiration catheter in patients with acute ischaemic stroke

Key facts

Study ID

NCT07571954

Run by

iVascular S.L.U.

People needed

45

Starts

2026-08-31

Expected to finish

2027-11-30

Last updated by the study team

2026-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects aged ≥ 18 years.
• Subjects able to be treated (i.e., defined by groin puncture time) within 24 hours of symptom onset or last time seen well.
• Occlusion in a large or proximal medium vessel (M1, proximal M2, A2 or P2) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
• Baseline NIHSS score ≥ 6 assessed before the procedure.
• Pre-stroke mRS score ≤ 2.
• Subjects with an ASPECTS score ≥ 6.
• Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).
• France-specific inclusion criteria: As applicable under French law, subjects affiliated with a health social security scheme or equivalent.

You may not qualify if…

• Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
• Severe allergy to contrast media.
• Women of child-bearing potential.
• Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
• Medical history of thrombocytopenia (Platelets <100,000).
• Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
• Subjects with occlusions in multiple vessels.
• Subjects with cancer who have a life expectancy of less than 6 months.
• Pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
• Severe sustained hypertension (systolic pressure >185 mm Hg or diastolic pressure >110 mm Hg). Note: If blood pressure can be successfully reduced and maintained at an acceptable level by administering the medication recommended by the ESO (European Stroke Organisation) in its guidelines (also IV infusion of antihypertensives), the subject may be included.
• Known or suspected cerebral vasculitis.
• Known renal insufficiency with creatinine ≥3 mg/dl or Glomerular Filtration Rate (GFR) <30 mL/min.
• Current participation in an interventional drug or device study that may confound the results of this study.
• Intracranial stenosis proximal to the occlusion.
• France-specific exclusion criteria: As applicable under French law, breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, or persons of legal age who are the subject of a legal protection measure.

Where it is running

• CHU Bordeaux (H Pellegrin) — Bordeaux, France
• CHU Lille — Lille, France
• Hospital Regional Universitario de Málaga Carlos Haya — Málaga, Andalusia, Spain
• Hospital Universitario Miguel Servet — Zaragoza, Aragon, Spain
• Hospital Clínico de Barcelona — Barcelona, Barcelona, Spain
• Hospital Universitario Bellvitge — L'Hospitalet de Llobregat, Catalonia, Spain
• Hospital Álvaro Cunqueiro — Vigo, Galicia, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.